Abstract
Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase that belongs to the Insulin receptor subfamily involved as full length receptor in neural development. Even if the expression of ALK protein is down-regulated in the adults, the ALK full length is expressed in different types of tumors. Moreover, chromosomal rearrangements, involving the alk gene, can occur leading to the formation of different ALK fusion proteins characterized by the kinase domain of ALK fused to several partners that determine cellular localization. Structural investigation and characterization of the ALK kinase domain in absence of its crystal structure constituted the basis of development of ALK small molecule inhibitors. Here, we described normal function of the ALK receptor and its role in tumors; formation of the constitutively activated ALK fusion proteins and we reported an update of developed small molecule inhibitors of the ALK kinase activity.
Keywords: Anaplastic Lymphoma kinase (ALK), Modeling, Molecular targeting, Oncogenic fusion protein, Small molecule inhibitors, Targeted cancer therapy, tyrosine kinase, alk gene, constitutively activated ALK fusion proteins, non-Hodgkin's lymphoma, Immunohystochemical studies, pleiotrophin(PTN) and midkine (MK), histological defects, glioblastoma, breast cancer
Current Topics in Medicinal Chemistry
Title: The ALK Gene, An Attractive Target for Inhibitor Development
Volume: 11 Issue: 11
Author(s): Carmen J. Tartari, Leonardo Scapozza and Carlo Gambacorti-Passerini
Affiliation:
Keywords: Anaplastic Lymphoma kinase (ALK), Modeling, Molecular targeting, Oncogenic fusion protein, Small molecule inhibitors, Targeted cancer therapy, tyrosine kinase, alk gene, constitutively activated ALK fusion proteins, non-Hodgkin's lymphoma, Immunohystochemical studies, pleiotrophin(PTN) and midkine (MK), histological defects, glioblastoma, breast cancer
Abstract: Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase that belongs to the Insulin receptor subfamily involved as full length receptor in neural development. Even if the expression of ALK protein is down-regulated in the adults, the ALK full length is expressed in different types of tumors. Moreover, chromosomal rearrangements, involving the alk gene, can occur leading to the formation of different ALK fusion proteins characterized by the kinase domain of ALK fused to several partners that determine cellular localization. Structural investigation and characterization of the ALK kinase domain in absence of its crystal structure constituted the basis of development of ALK small molecule inhibitors. Here, we described normal function of the ALK receptor and its role in tumors; formation of the constitutively activated ALK fusion proteins and we reported an update of developed small molecule inhibitors of the ALK kinase activity.
Export Options
About this article
Cite this article as:
J. Tartari Carmen, Scapozza Leonardo and Gambacorti-Passerini Carlo, The ALK Gene, An Attractive Target for Inhibitor Development, Current Topics in Medicinal Chemistry 2011; 11 (11) . https://dx.doi.org/10.2174/156802611795589593
DOI https://dx.doi.org/10.2174/156802611795589593 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Selective Histone Deacetylase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Severe Hypoglycemia Due to Possible Interaction Between Glibenclamide and Sorafenib in a Patient with Hepatocellular Carcinoma
Current Drug Safety Editorial (Thematic Issue: From Gut Inflammation to Gastrointestinal Disorders Current Update on Pathophysiology, Molecular Mechanism and Pharmacological Treatment Modalities)
Current Pharmaceutical Design Tumor-selective Cytotoxicity of a Novel Pentadiene Analogue on Human Leukemia/lymphoma Cells
Clinical Cancer Drugs Natural New Sesquiterpenes: Structural Diversity and Bioactivity
Current Organic Chemistry Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry Fingerprint-based 2D-QSAR Models for Predicting Bcl-2 Inhibitors Affinity
Letters in Drug Design & Discovery A Pocket Guide to Explorations of the Defensin Field
Current Pharmaceutical Design Aberrant Splicing, Hyaluronan Synthases and Intracellular Hyaluronan as Drivers of Oncogenesis and Potential Drug Targets
Current Cancer Drug Targets Signaling Pathways Responsible for Cancer Cell Invasion as Targets for Cancer Therapy
Current Cancer Drug Targets Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment
Current Medicinal Chemistry Chinese Herbs as Immunomodulators and Potential Disease-Modifying Antirheumatic Drugs in Autoimmune Disorders
Current Drug Metabolism Synthesis and <i>In Vitro</i> Cytotoxic Evaluation of Novel Murrayafoline A Derived β-Amino Alcohols
Letters in Organic Chemistry Comprehensive Profiling of Protein Ubiquitination for Drug Discovery
Current Pharmaceutical Design Functions of S100 Proteins
Current Molecular Medicine Ceramide and Apoptosis: Exploring the Enigmatic Connections between Sphingolipid Metabolism and Programmed Cell Death
Anti-Cancer Agents in Medicinal Chemistry Zevalin™: 90Yttrium Labeled Anti-CD20 (Ibritumomab Tiuxetan), a New Treatment for Non-Hodgkin ’ s Lymphoma
Current Pharmaceutical Biotechnology Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Enhanced Activity of pSTAT-3 Ser-727 in Functional Endothelial Cells Under Calcifying Conditions
Current Chemical Biology B Cell Responses to Oxidative Stress
Current Pharmaceutical Design